9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The CD38 cell surface antigen is expressed in diverse hematologic malignancies including multiple myeloma, B-cell non-Hodgkin lymphoma (NHL), B-cell chronic lymphocytic leukemia, B-cell acute lymphoblastic leukemia (ALL), and T-cell ALL. Here, we assessed the antitumor activity of the anti-CD38 antibody SAR650984.

          Related collections

          Author and article information

          Journal
          Clin. Cancer Res.
          Clinical cancer research : an official journal of the American Association for Cancer Research
          1078-0432
          1078-0432
          Sep 1 2014
          : 20
          : 17
          Affiliations
          [1 ] Research and Development, ImmunoGen, Inc., Waltham, Massachusetts. jutta.deckert@immunogen.com.
          [2 ] Oncology Business Division, Sanofi R&D, Vitry-sur-Seine, France.
          [3 ] Research and Development, ImmunoGen, Inc., Waltham, Massachusetts.
          [4 ] SCP LGCR/Structure Design & Informatics/Structural Biology, Sanofi R&D, Vitry-sur-Seine, France.
          [5 ] Biorealization/Operations and Protein Tools, Sanofi R&D, Vitry-sur-Seine, France.
          [6 ] Hematology Laboratory, Hospices Civils de Lyon, Pierre Bénite, France and CRCL, INSERM 1052-CNRS 5286, Lyon, France.
          Article
          1078-0432.CCR-14-0695
          10.1158/1078-0432.CCR-14-0695
          24987056
          ©2014 American Association for Cancer Research.

          Comments

          Comment on this article